Tetanus – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tetanus – Pipeline Review, H2 2016’, provides an overview of the Tetanus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Tetanus

The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects

The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Tetanus

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Tetanus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co., Ltd

Bharat Biotech International Limited

BioClonetics Immunotherapeutics, Inc.

Biological E. Limited

Boryung Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

GlaxoSmithKline Plc

Green Cross Corporation

Indian Immunologicals Limited

Kaketsuken K.K.

LG Life Science LTD.

Panacea Biotec Limited

Prometheon Pharma, LLC

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Tetanus Overview 10

Therapeutics Development 11

Pipeline Products for Tetanus - Overview 11

Pipeline Products for Tetanus - Comparative Analysis 12

Tetanus - Therapeutics under Development by Companies 13

Tetanus - Therapeutics under Investigation by Universities/Institutes 15

Tetanus - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Tetanus - Products under Development by Companies 19

Tetanus - Products under Investigation by Universities/Institutes 21

Tetanus - Companies Involved in Therapeutics Development 22

Beijing Minhai Biotechnology Co., Ltd 22

Bharat Biotech International Limited 23

BioClonetics Immunotherapeutics, Inc. 24

Biological E. Limited 25

Boryung Pharmaceutical Co., Ltd. 26

Daiichi Sankyo Company, Limited 27

GlaxoSmithKline Plc 28

Green Cross Corporation 29

Indian Immunologicals Limited 30

Kaketsuken K.K. 31

LG Life Science LTD. 32

Panacea Biotec Limited 33

Prometheon Pharma, LLC 34

Sanofi Pasteur SA 35

Serum Institute of India Limited 36

Sinovac Biotech Ltd. 37

Zydus Cadila Healthcare Limited 38

Tetanus - Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

(diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

(diphtheria + tetanus) vaccine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Eupenta - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

GC-1107 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

GC-3111A - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

KD-370 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

LBVD - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Monoclonal Antibody for Tetanus - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Monoclonal Antibody for Tetanus - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Monoclonal Antibody to Target Tetanus Toxin for Tetanus - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

tetanus vaccine - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

tetanus vaccine - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

tetanus vaccine - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

tetanus vaccine - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

VN-0103 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

VN-0105 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Tetanus - Dormant Projects 86

Tetanus - Discontinued Products 88

Tetanus - Product Development Milestones 89

Featured News & Press Releases 89

Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 89

Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA 89

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 89

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 90

Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 91

Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 92

Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 92

Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 93

Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 94

Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 95

Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 95

Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 96

Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 96

Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. 97

May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children 98

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Tables

List of Tables

Number of Products under Development for Tetanus, H2 2016 11

Number of Products under Development for Tetanus – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Tetanus – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 22

Tetanus – Pipeline by Bharat Biotech International Limited, H2 2016 23

Tetanus – Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 24

Tetanus – Pipeline by Biological E. Limited, H2 2016 25

Tetanus – Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016 26

Tetanus – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 27

Tetanus – Pipeline by GlaxoSmithKline Plc, H2 2016 28

Tetanus – Pipeline by Green Cross Corporation, H2 2016 29

Tetanus – Pipeline by Indian Immunologicals Limited, H2 2016 30

Tetanus – Pipeline by Kaketsuken K.K., H2 2016 31

Tetanus – Pipeline by LG Life Science LTD., H2 2016 32

Tetanus – Pipeline by Panacea Biotec Limited, H2 2016 33

Tetanus – Pipeline by Prometheon Pharma, LLC, H2 2016 34

Tetanus – Pipeline by Sanofi Pasteur SA, H2 2016 35

Tetanus – Pipeline by Serum Institute of India Limited, H2 2016 36

Tetanus – Pipeline by Sinovac Biotech Ltd., H2 2016 37

Tetanus – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 38

Assessment by Monotherapy Products, H2 2016 39

Assessment by Combination Products, H2 2016 40

Number of Products by Stage and Target, H2 2016 42

Number of Products by Stage and Route of Administration, H2 2016 44

Number of Products by Stage and Molecule Type, H2 2016 46

Tetanus – Dormant Projects, H2 2016 86

Tetanus – Dormant Projects (Contd..1), H2 2016 87

Tetanus – Discontinued Products, H2 2016 88

List of Figures

List of Figures

Number of Products under Development for Tetanus, H2 2016 11

Number of Products under Development for Tetanus – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 39

Assessment by Combination Products, H2 2016 40

Number of Products by Targets, H2 2016 41

Number of Products by Stage and Targets, H2 2016 41

Number of Products by Routes of Administration, H2 2016 43

Number of Products by Stage and Routes of Administration, H2 2016 43

Number of Products by Molecule Types, H2 2016 45

Number of Products by Stage and Molecule Types, H2 2016 45

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports